Pitavastatin-d4 hemicalcium(Synonyms: NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Pitavastatin-d4 hemicalcium (Synonyms: NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium)

Pitavastatin-d4 (hemicalcium) 是 Pitavastatin (Calcium) 氘代物。Pitavastatin Calcium (NK-104 hemicalcium) 是有效的羟甲基戊二酰-CoA (HMG-CoA) 还原酶抑制剂。Pitavastatin Calcium 在 HepG2 细胞中抑制乙酸合成胆固醇的 IC50 为 5.8 nM。Pitavastatin Calcium 是一种高效的肝细胞低密度脂蛋白胆固醇 (LDL-C) 受体诱导剂。具有抗癌活性。

Pitavastatin-d4 hemicalcium(Synonyms: NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium)

Pitavastatin-d4 hemicalcium Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

444.52

Formula

C25H19D4FNO.1/2Ca2+
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Mukhtar RY, et al. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-52.

    [3]. Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003 Fall;21(3):199-215.

    [4]. de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7(1):5410.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复